Amrutanjan Health Care Q1 FY27 Results

Revenue from operations ₹102.97 crore; Profit After Tax ₹4.37 crore.

Reader Takeaway: Top-line growth with a one-time charge impacting profit, lease dispute resolved.

What Just Happened

Amrutanjan Health Care reported its financial results for the quarter ended June 30, 2026. Revenue from operations increased by 9.4% to ₹102.97 crore from ₹94.05 crore in the same quarter last year. However, Profit After Tax (PAT) saw a significant decrease, falling to ₹4.37 crore from ₹8.31 crore in the year-ago period. This drop was partly due to an exceptional expense of ₹2.03 crore related to the settlement of a lease rent dispute with the Tamil Nadu Government, resolved on August 1, 2026.

Why This Matters

The revenue growth indicates sustained demand for Amrutanjan's products. The resolution of the lease rent dispute is a positive development as it removes a long-standing contingent liability. While the exceptional charge impacted the current quarter's profitability, its one-time nature means future profits may not carry this burden. Investors will be watching how the core segments perform going forward.

The Backstory

Amrutanjan Health Care has been a player in the consumer healthcare space for decades. The company operates across several segments, including Over-the-Counter (OTC) Products, Women's Hygiene & Personal Care, and Beverages. The recent settlement of the lease rent dispute with the Tamil Nadu Government addresses a legacy issue that had been outstanding.

What Changes Now

With the lease rent dispute settled, the company can focus entirely on operational growth without the overhang of this legal matter. The settlement on August 1, 2026, will reflect in future financials as a closed item. The company has also announced its 89th AGM for September 23, 2026, and set the dividend record date for September 11, 2026.

Risks to Watch

While the lease dispute is resolved, the company faces ongoing competition in the FMCG and healthcare sectors. Maintaining consistent profitability amidst rising costs and market dynamics will be a key challenge. The reported dip in PAT, even excluding the exceptional item, suggests margin pressures might need monitoring.

Peer Comparison

While specific peer performance data for the same quarter isn't immediately available from this filing, Amrutanjan competes with various players in the OTC analgesic, personal care, and beverage markets. Companies like Dabur India, Emami, and Marico operate in similar consumer-focused segments.

Context Metrics (Time-Bound)

Revenue from Operations (Quarter Ended June 30, 2026): ₹102.97 crore (₹10,296.88 lakh).
Profit After Tax (Quarter Ended June 30, 2026): ₹4.37 crore (₹436.57 lakh).
Exceptional Item (Lease Rent Settlement): ₹2.03 crore (₹202.75 lakh).
Revenue from Operations (Quarter Ended June 30, 2025): ₹94.05 crore (₹9,404.57 lakh).
Profit After Tax (Quarter Ended June 30, 2025): ₹8.31 crore (₹831.12 lakh).

What to Track Next

Investors should monitor the company's performance in the upcoming quarters to see the impact of the resolved lease dispute on profitability. Continued revenue growth from its core OTC and Women's Hygiene segments will be crucial. Updates on corporate actions, including dividend payout and AGM proceedings, are also important.